Literature DB >> 32474469

Proteomic Profiling of Plasma and Brain Tissue from Alzheimer's Disease Patients Reveals Candidate Network of Plasma Biomarkers.

Mei Chen1, Weiming Xia1,2.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most prevalent form of dementia with two pathological hallmarks of tau-containing neurofibrillary tangles and amyloid-β protein (Aβ)-containing neuritic plaques. Although Aβ and tau have been explored as potential biomarkers, levels of these pathological proteins in blood fail to distinguish AD from healthy control subjects.
OBJECTIVE: We aim to discover potential plasma proteins associated with AD pathology by performing tandem mass tag (TMT)-based quantitative proteomic analysis of proteins from peripheral and central nervous system compartments.
METHODS: We performed comparative proteomic analyses of plasma collected from AD patients and cognitively normal subjects. In addition, proteomic profiles from the inferior frontal cortex, superior frontal cortex, and cerebellum of postmortem brain tissue from five AD patients and five non-AD controls were compared with plasma proteomic profiles to search for common biomarkers. Liquid chromatography-mass spectrometry was used to analyze plasma and brain tissue labeled with isobaric TMT for relative protein quantification.
RESULTS: Our results showed that the proteins in complement coagulation cascade and interleukin-6 signaling were significantly altered in both plasma and brains of AD patients.
CONCLUSION: Our results demonstrate the relevance in immune responses between the peripheral and central nervous systems. Those differentially regulated plasma proteins are explored as candidate biomarker profiles that illustrate chronic neuroinflammation in brains of AD patients.

Entities:  

Keywords:  Alzheimer’s disease; biomarker; mass spectrometry; plasma; quantitative proteomics; tandem mass tag (TMT)

Mesh:

Substances:

Year:  2020        PMID: 32474469      PMCID: PMC7457324          DOI: 10.3233/JAD-200110

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.160


  114 in total

1.  Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease.

Authors:  Yao-Hsiang Shih; Kuen-Jer Tsai; Chu-Wan Lee; Shu-Chu Shiesh; Wei-Ting Chen; Ming-Chyi Pai; Yu-Min Kuo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

3.  Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells.

Authors:  Y Chong
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

Review 4.  Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer's Disease.

Authors:  Kun Ping Lu; Yih-Cherng Liou; Inez Vincent
Journal:  Bioessays       Date:  2003-02       Impact factor: 4.345

5.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

6.  Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release.

Authors:  Lili Donner; Knut Fälker; Lothar Gremer; Stefan Klinker; Giulia Pagani; Liza U Ljungberg; Kimberley Lothmann; Federica Rizzi; Martin Schaller; Holger Gohlke; Dieter Willbold; Magnus Grenegard; Margitta Elvers
Journal:  Sci Signal       Date:  2016-05-24       Impact factor: 8.192

7.  A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.

Authors:  Hedieh Shahpasand-Kroner; Hans-W Klafki; Chris Bauer; Johannes Schuchhardt; Melanie Hüttenrauch; Martina Stazi; Caroline Bouter; Oliver Wirths; Jonathan Vogelgsang; Jens Wiltfang
Journal:  Alzheimers Res Ther       Date:  2018-12-08       Impact factor: 6.982

Review 8.  Blood-based molecular biomarkers for Alzheimer's disease.

Authors:  Henrik Zetterberg; Samantha C Burnham
Journal:  Mol Brain       Date:  2019-03-28       Impact factor: 4.041

9.  Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.

Authors:  Sarah Westwood; Alison L Baird; Sneha N Anand; Alejo J Nevado-Holgado; Andrey Kormilitzin; Liu Shi; Abdul Hye; Nicholas J Ashton; Angharad R Morgan; Isabelle Bos; Stephanie J B Vos; Susan Baker; Noel J Buckley; Mara Ten Kate; Philip Scheltens; Charlotte E Teunissen; Rik Vandenberghe; Silvy Gabel; Karen Meersmans; Sebastiaan Engelborghs; Ellen E De Roeck; Kristel Sleegers; Giovanni B Frisoni; Olivier Blin; Jill C Richardson; Régis Bordet; José L Molinuevo; Lorena Rami; Anders Wallin; Petronella Kettunen; Magda Tsolaki; Frans Verhey; Alberto Lléo; Isabel Sala; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Peter Johannsen; Yvonne Freund-Levi; Lutz Frölich; Valerija Dobricic; Cristina Legido-Quigley; Lars Bertram; Frederik Barkhof; Henrik Zetterberg; B Paul Morgan; Johannes Streffer; Pieter Jelle Visser; Simon Lovestone
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Proteome-based plasma biomarkers for Alzheimer's disease.

Authors:  A Hye; S Lynham; M Thambisetty; M Causevic; J Campbell; H L Byers; C Hooper; F Rijsdijk; S J Tabrizi; S Banner; C E Shaw; C Foy; M Poppe; N Archer; G Hamilton; J Powell; R G Brown; P Sham; M Ward; S Lovestone
Journal:  Brain       Date:  2006-11       Impact factor: 13.501

View more
  6 in total

1.  Plasma proteome profiling identifies changes associated to AD but not to FTD.

Authors:  R Babapour Mofrad; M Del Campo; C F W Peeters; L H H Meeter; H Seelaar; M Koel-Simmelink; I H G B Ramakers; H A M Middelkoop; P P De Deyn; J A H R Claassen; J C van Swieten; C Bridel; J J M Hoozemans; P Scheltens; W M van der Flier; Y A L Pijnenburg; Charlotte E Teunissen
Journal:  Acta Neuropathol Commun       Date:  2022-10-22       Impact factor: 7.578

2.  Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma.

Authors:  Mostafa J Khan; Heather Desaire; Oscar L Lopez; M Ilyas Kamboh; Renã A S Robinson
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.160

3.  Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry.

Authors:  Yeongshin Kim; Jaenyeon Kim; Minsoo Son; Jihyeon Lee; Injoon Yeo; Kyu Yeong Choi; Hoowon Kim; Byeong C Kim; Kun Ho Lee; Youngsoo Kim
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

4.  Serum Glycoproteomics and Identification of Potential Mechanisms Underlying Alzheimer's Disease.

Authors:  Naphatthakarn Kerdsaeng; Sittiruk Roytrakul; Suwannee Chanprasertyothin; Piangporn Charernwat; Sirintorn Chansirikarnjana; Piyamitr Sritara; Jintana Sirivarasai
Journal:  Behav Neurol       Date:  2021-12-11       Impact factor: 3.342

Review 5.  Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases.

Authors:  Artur Schumacher-Schuh; Andrei Bieger; Wyllians V Borelli; Makayla K Portley; Paula Saffie Awad; Sara Bandres-Ciga
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.003

6.  Prognosis of Alzheimer's Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning.

Authors:  Alexey S Kononikhin; Natalia V Zakharova; Savva D Semenov; Anna E Bugrova; Alexander G Brzhozovskiy; Maria I Indeykina; Yana B Fedorova; Igor V Kolykhalov; Polina A Strelnikova; Anna Yu Ikonnikova; Dmitry A Gryadunov; Svetlana I Gavrilova; Evgeny N Nikolaev
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.